Seres Therapeutics, Inc. (MCRB) Financial Statements (2024 and earlier)

Company Profile

Business Address 200 SIDNEY STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments181,341290,706253,61694,81685,820149,983
Cash and cash equivalents163,030180,002116,04965,12685,82036,088
Short-term investments 18,311110,704137,56729,690 113,895
Receivables   9,3871,785  
Inventory, net of allowances, customer advances and progress billings      
Inventory      
Other undisclosed current assets13,42312,9225,7743,5886,8455,095
Total current assets:194,764303,628268,777100,18992,665155,078
Noncurrent Assets
Operating lease, right-of-use asset110,98418,2089,04111,356
Property, plant and equipment22,98517,93813,89719,49526,29432,931
Long-term investments and receivables  49549,825   
Long-term investments  49549,825   
Restricted cash and investments9,5869,4011,4001,4001,5131,513
Other noncurrent assets10,4655,189    
Total noncurrent assets:154,02051,23174,16332,25127,80734,444
TOTAL ASSETS:348,784354,859342,940132,440120,472189,522
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities35,79326,58411,90510,13814,57615,636
Employee-related liabilities9,2166,7344,6095,0204,962
Accounts payable17,44013,7354,0184,8596,4157,033
Accrued liabilities18,3533,6331,1536703,1413,641
Deferred revenue    4,834
Debt 456 4544,456  
Due to related parties34,77021,098    
Contract with customer, liability20,419
Other undisclosed current liabilities14,57734,57634,05626,5657,04615,989
Total current liabilities:85,59682,25846,41545,99342,04131,625
Noncurrent Liabilities
Long-term debt and lease obligation50,59142,60135,20040,324  
Long-term debt, excluding current maturities50,59124,64324,63924,648  
Liabilities, other than long-term debt109,38422,0801,0035,336119,2263,362
Deferred revenue and credits2,233
Deferred revenue    4,834
Contract with customer, liability116,840
Deferred rent credit     2,216
Due to related parties 10,585    
Other liabilities1,44211,4951,0035021701,129
Operating lease, liability107,94217,95810,56115,676
Derivative instruments and hedges, liabilities      
Other undisclosed noncurrent liabilities92,43076,41385,57289,1117,25093,836
Total noncurrent liabilities:252,405141,094121,775134,771126,47697,198
Total liabilities:338,001223,352168,190180,764168,517128,823
Equity
Equity, attributable to parent10,783131,507174,750(48,324)(48,045)60,699
Common stock1259291704140
Additional paid in capital875,181745,829723,482411,255341,284324,376
Accumulated other comprehensive loss (12)(60)(47)  (146)
Accumulated deficit(864,511)(614,354)(548,776)(459,649)(389,370)(263,571)
Total equity:10,783131,507174,750(48,324)(48,045)60,699
TOTAL LIABILITIES AND EQUITY:348,784354,859342,940132,440120,472189,522

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues7,128144,92733,21534,50528,26732,100
Revenue, net32,100
Revenue from related parties    26,917
Gross profit:7,128144,92733,21534,50528,26732,100
Operating expenses(253,618)(209,420)(121,345)(106,381)(128,551)(123,495)
Operating loss:(246,490)(64,493)(88,130)(71,876)(100,284)(91,395)
Nonoperating income (expense)(3,667)(1,085)(997)1,5971,3422,015
Investment income, nonoperating3,0582,8709461,033  
Other nonoperating income (expense)(705)(1,045)9811,066170425
Interest and debt expense(6,020)(2,910)(446)(502)  
Loss from continuing operations:(256,177)(68,488)(89,573)(70,781)(98,942)(89,380)
Loss before gain (loss) on sale of properties:(68,488)(89,573)(70,781)(98,942)(89,380)
Net loss:(256,177)(68,488)(89,573)(70,781)(98,942)(89,380)
Other undisclosed net income attributable to parent6,0202,910446502  
Net loss available to common stockholders, diluted:(250,157)(65,578)(89,127)(70,279)(98,942)(89,380)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(256,177)(68,488)(89,573)(70,781)(98,942)(89,380)
Other comprehensive income      3
Comprehensive loss:(256,177)(68,488)(89,573)(70,781)(98,942)(89,377)
Other undisclosed comprehensive income, net of tax, attributable to parent6,0682,897399502146 
Comprehensive loss, net of tax, attributable to parent:(250,109)(65,591)(89,174)(70,279)(98,796)(89,377)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: